The Tisch Cancer Institute | Strategic Alliance Partners

Latest from The Tisch Cancer Institute

Liquid Biopsies and Molecular Testing in NSCLC

April 09, 2021

Nicholas C. Rohs, MD, Isabel Preeshagul, DO, MBS, and Joshua K. Sabari, MD, discuss the significance of molecular testing in clinical practice and the evolution of liquid biopsies in lung cancer treatment.

Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity

January 19, 2021

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.